Global Perspectives on Coronary Artery Disease: The Emerging Role of miRNAs.

PURPOSE OF REVIEW

The purpose of this review is to provide an in-depth exploration of the role of microRNAs (miRNAs) in the pathogenesis of coronary artery disease (CAD). Specifically, the review focuses on how miRNAs influence endothelial dysfunction, smooth muscle cell activity, and inflammatory responses, all of which contribute to the development and progression of CAD. Additionally, the review highlights the potential of circulating miRNAs as non-invasive diagnostic biomarkers and discusses their therapeutic potential in managing CAD. However, challenges remain in translating miRNA research into clinical practice, particularly concerning delivery mechanisms, specificity, and off-target effects, which are critical to overcoming before widespread clinical application.

RECENT FINDINGS

Recent research has identified over 50 miRNAs as critical regulators of vascular homeostasis and CAD progression, playing significant roles in atherosclerotic plaque development, endothelial cell senescence, and impaired vascular repair. Certain miRNAs have been found to influence inflammatory pathways within atherosclerotic plaques, contributing to plaque instability and rupture, which are key events in acute coronary syndromes (ACS), such as myocardial infarction (MI) and unstable angina (UA). Furthermore, circulating miRNAs have emerged as promising non-invasive biomarkers for early detection, risk assessment, and therapeutic targeting in CAD. This review underscores the importance of miRNAs in the pathophysiology of CAD, highlighting their roles in endothelial dysfunction, smooth muscle cell behavior, and inflammatory responses. By modulating these processes, miRNAs contribute to the progression of atherosclerosis and the onset of ACS. The potential of circulating miRNAs as diagnostic tools and therapeutic targets offers new avenues for improving the management and outcomes of CAD. The review aims to lay the groundwork for future research and the development of miRNA-based therapies that could transform the landscape of CAD treatment, reshaping current therapeutic approaches and significantly improving patient outcomes.